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Thrombotic phenomena are well-recognized complications ofnephrotic syndrome attrib- 
utable to loss of intermediate-sized antithrombotic proteins in the urine, resulting in a 
hypercoaguable state. As such, nephrotic syndrome may be associated with a reduction in 
circulating antithrombin III and free protein S levels. Associated spontaneous throm- 
boric complications are generally venous in antre, with arterial thrombosis occurring 
less frequently. Hypercoagulability caused by acquired nephrotic syndrome has not 
generally been recognized as a cause of acute thrombosis of arterial bypass grafts. We 
report wo patients who after having nephrotic syndrome sustainedacute thrombosis of 
their arterial bypass grafts. Pathogenesis and management are discussed. (J Vase Surg 
1997;25:576-80.) 
The clinical manifestations of nephrotic syn- 
drome are attributable to the reduced ability of  the 
glomerular barrier to exclude proteins of intermedi- 
ate size from the urine. 1 Very large proteins remain 
excluded from the glomerular ultrafiltrate ven when 
barrier function is severely disrupted. Proteins lost in 
the urine include albumin and proteins involved in 
modulation of the coagulation cascade, such as pro- 
tein S and antithrombin III. Pathophysiologic 
changes are a consequence of the nature of the pro- 
teins lost and of the proteins that are increased in 
plasma to replace them. Thromboembolic complica£ 
tions of nephrotic syndrome have been well de- 
scribed, beginning with Addis 2 in 1948, who re- 
ferred to the frequent occurrence of venous 
thrombosis during the degenerative state of glomer- 
ulonephritis. Although venous thrombosis i a well- 
recognized complication of the hypercoaguable 
state, thrombosis involving the arterial system is 
much more unusual and is mainly reported in ne- 
phrotic children. 3-s Even more unusual are reports of 
arterial bypass graft occlusion. 6 We describe two 
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cases of arterial bypass graft thrombosis caused by 
acquired nephrotic syndrome and discuss the patho- 
genesis and management of this unusual but poten- 
tially disastrous complication. 
CASE REPORTS 
Case 1. A 52-year-old man with a history of left 
below-knee amputation 3 years earlier sought medical at- 
tention with acute ischemia of the right leg and left stump 
6 months after he underwent aortobifemoral bypass graft- 
ing. Current medications included fluoxetine (Prozac), re- 
cently prescribed for clinical depression. Hematocrit was 
39.5%, and platelet count was 186,000/ml. Serum sodium 
was 126 mEq/L, blood urea nitrogen 13 mg/dl, creati- 
nine 0.8 mg/di, and albumin 3.5 mg/di. Urinalysis revealed 
greater than 2000 mg/dl of protein. Thrombectomy of
the right aortofemoral graft limb and a fernorofemoral 
bypass were performed without technical difficulty. Pa- 
tency o f~e left limb of the aortofemoral bypass could not 
be reestablished. However, graft patency could not be 
maintained during surgery despite heparin administration. 
Intraoperative arteriography of the right aortofemoral graft 
limb revealed normal inflow. Preoperative hyponatremia 
raised the issue of nephrotic syndrome. After 4 U of fresh- 
frozen plasma and additional heparin were administered, 
graft patency was restored and maintained. Protein S and 
antithrombin III levels drawn immediately after surgery 
were reduced to 39% (NL 70 to 140) and 70% (NL 80 to 
120), respectively, whereas protein C activity was within 
normal limits. Twenty-four hour urinary protein excretion 
was 4.3 gm. The acquired nephrotic syndrome was be- 
lieved to be Prozac-induced, because the proteinuria re- 
solved over a period of several months after Prozac was 
discontinued, with return of protein S and antithrombin 
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III levels to a normal range. The patient received warfarin 
until the nephrotic syndrome resolved, after which it was 
discontinued. The graft has remained continuously patent 
over a period of 16 months. 
Case 2. A 61-year-old man had an acutely ischemic 
left leg. He had noted the new onset of claudication coin- 
ciding with the diagnosis of biopsy-proven membrano- 
proliferative glomerulonephritis 1 month before admission. 
His surgical history was significant for a left femoropopli- 
teal bypass with reversed saphenous vein 16 years earlier. 
The hematocrit level was 40.2%, and platelet count was 
110,000/ml. Serum creatinine was 2.2 mg/dl, blood urea 
nitrogen 117 mg/dl, and albumin 1.6 mg/dl. Urinalysis 
revealed greater than 2000 mg/dl of protein. Transfemo- 
ral arteriography revealed total occlusion of the bypass 
graft. Heparin therapy was instituted, followed by uroki- 
nase thrombolysis and angioplasty of a native outflow 
vessel, which was successful in restoring raft patency. 
Protein S activity was reduced to 37% (NL 70 to 140), 
whereas protein C and antithrombin III levels were 
within normal imits. Twenty-four hour urinary protein 
excretion was 4.6 gm, and coumadin therapy was begun. 
However, over a period of several weeks progressive 
renal failure requiring hemodialysis ensued, eventuating 
in anuria. The accompanying cessation of proteinuria 
resulted in a return of protein S activity to normal levels 
(78%), hence long-term anticoagulation was not 
deemed necessary. 
DISCUSSION 
Nephrotic syndrome is characterized by heavy 
proteinuria of greater than 3.5 gm over a 24-hour 
period, hypoalbumemia, edema, hyperlipidemia, and 
on occasion, renal failure. 7 Although most patients 
with nephrotic syndrome have each of these signs at 
some time during the course of their illness, the 
diagnosis can be made on the basis of heavy protein- 
uria alone. Nephrotic syndrome results from glomer- 
ular disease caused by changes in the characteristics 
of the glomerular basement membrane and leading 
to alterations in the filtration process. 8 As a result 
there is a marked filtration of albumin and other 
intermediate-sized proteins into Bowman's space. 
Nephrotic syndrome can be divided into two major 
groups of disorders depending on whether it is pri- 
mary or secondary. In a review of 56 patients with 
arterial thrombosis, it was found that 14% of the 
cases were the result of membranoproliferative glo-
merulonephritis. 6 Several drugs including Prozac 
have been associated with histologic hanges consis- 
tent with nephrotic syndrome, which usually resolve on 
withdrawal of the offending drug. 9 
The propensity of patients with nephrotic syn- 
drome to have venous and arterial thrombosis has 
been attributed to a hypercoaguable state, the patho- 
genesis of which is multifactorial. Deficiencies in the 
coagulation i hibitors antithrombin III and protein 
S play a major role in generating the increased risk of 
thrombosis in patients with nephrotic syndrome. In- 
creased blood and plasma viscosity caused by 
hemoconcentration a d elevated fibrinogen levels 
aggravated by the use of diuretics contributes to a 
hypercoagulability.10 Steroids often used to treat his 
condition can increase the concentration of clotting 
factor VIII and shorten prothrombin and partial 
thromboplastin times, n,12 Thrombocytosis, increased 
platelet aggregation, and adhesiveness associated 
with nephrotic syndrome may also contribute to the 
generation of thromboembolic complications. 13 De- 
creased fibrinolytic activity associated with hypertri- 
glyceridemia and decreased plasma plasminogen cor- 
relating with the magnitude of proteinuria has been 
observed as well. 14 In addition, nephrotic syndrome 
is characterized bya profound change in the turnover 
and concentration fmany plasma proteins including 
those involved in the coagulation cascade. Factors 
IX, XI, and XII are decreased through urinary loss, 
whereas procoagulant factors II, V, VII, VIII, X, and 
XIII are increased, both correlating with the degree 
of reduction in serum albumin. 15-18 
The coagulation cascade consists of a highly reg- 
ulated system of enzymes and cofactors that interact 
to eventually produce thrombin.19 The procoagulant 
effects of thrombin include activation of factors V 
and VIII in a positive feedback reaction, proteolytic 
conversion of soluble fibrinogen to insoluble fibrin, 
activation of factor XIII causing cross-linldng of in- 
soluble fibrin, and activation and aggregation of 
platelets. Pathologic thrombin generation leading to 
thrombus formation is counteracted by several phys- 
iologic anticoagulants including antithrombin III, 
the vitamin-K dependent cofactors protein S and 
protein C (Fig. 1), and by the newly described tissue 
factor pathway inhibitor. 2° 
In 1965 Egeberg 21 first noted an association be- 
tween antithrombin III deficiency and thromboem- 
bolic complications. Antithrombin 111 is a serine pro- 
tease inhibitor synthesized by the liver and endothelial 
cells that interacts with thrombin and other serine 
proteases in a progressive irreversible manner. 22 Al- 
though with less efficiency, antithrombin III also 
inactivates factors Xa, IXa, XIa, XIIa, and kallikrein. 
Antithrombin III can also function as a heparin co- 
factor necessary for heparin anticoagulant activity. 
Heparin markedly enhances the antifactor Xa activity 
of antithrombin Ill. 23 Inactivation of thrombin and 
factor Xa by antithrombin I l i  occurs through the 
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Fig. 1. Inhibition of thrombin activity by protein S and protein C. Deficiency of protein S as 
result of urinary loss in setting of nephrotic syndrome precludes formation of activated protein 
C-protein S complex required for inhibition of thrombin activity. 
interaction of heparin with antithrombin or by the 
interaction of heparin with a specific protease. 24 In 
the presence of heparin the preferential target of 
antithrombin III is thrombin, followed by factor Xa. 
Plasma concentration of antithrombin III is de- 
creased in patients with nephrotic syndrome as a 
result of increased filtration through the glomerular 
basement membrane. 2s Increased urinary concentra- 
tions of antithrombin III have been measured in 
patients with nephrotic syndrome along with de- 
creased serum levels, both of which correlated with 
decreased serum albumin levels. 26,27 Individuals with 
antithrombin III deficiency carry a 50% to 70% life- 
time risk of having thrombotic omplications. 28 Sur- 
gery without replacement ofantithrombin III carries 
a high risk of thrombotic omplications. Low levels 
of antithrombin III have been shown to occur in up 
to 80% of patients with nephrosis. 29 However, 
thromboembolic complications also occur in patients 
with normal antithrombin III levels and nephrotic 
syndrome, indicating that although antithrombin III
is a major determinant ofplasma ntithrombin activ- 
ity, it is not the only one, because other regulatory 
proteins of the coagulation cascade play a role. 4 
After activation by thrombin occurs, activated 
protein C acts as a major inhibitor of blood coagula- 
tion as it proteolytically degrades factors Va and 
VIIIa, resulting in inhibition of coagulation. Protein 
S, a vitamin K-dependent plasma protein, serves as a 
cofactor for the anticoagulant activity of activated 
protein C, another vitamin K-dependent protein) ° 
Only approximately 40% of protein S is unbound and 
able to act as a cofactor for activated protein C. The 
remaining 60% of protein S is bound to C4b-binding 
protein and as such does not participate in the coag- 
ulation cascade) 1 Acquired protein S deficiency can 
occur in a variety of clinical conditions including 
nephrotic syndrome. Vigano-D'Angelo et al.32 ob- 
served low free protein S levels in patients with ne- 
phrotic syndrome despite having elevated levels of 
total protein S antigen. They were able to demon- 
strate a urinary loss of free protein S and increased 
C4b-binding protein leading to a shift from free to 
bound protein S, thereby resulting in a pronounced 
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decrease in free protein S. Therefore lowered free 
protein S levels in nephrotic syndrome can be attrib- 
uted to urinary loss of low-molecular-weight free 
protein S and to increased high-molecular-weight 
C4b-binding protein bound to protein S, resulting in 
a hypercoaguable state. Protein C activity is generally 
normal in nephrotic patients or may even be ele- 
vated. 
The management of graft thrombosis in patients 
with acquired nephrotic syndrome rests on early rec- 
ognition of the hypercoagulable state, establishment 
of adequate anticoagulation, and elimination of the 
offending agent. Because heparin exerts its anticoag- 
ulant effect by potentiating the effects of antithrom- 
bin III, high-dose heparin therapy may be necessary 
to achieve anticoagularion in the setting of anti- 
thrombin III deficiency. 33 However, it may not be 
possible to effect anticoagulation without first replac- 
ing antithrombin III by transfusion of fresh-frozen 
plasma, as described by Karl et al., 34 or by adminis- 
tration of antithrombin III concentrates. 35 If ne- 
phrosis-induced thrombosis is suspected and heparin 
alone cannot achieve anticoagulation, transfusion of 
fresh-frozen plasma, a source of both antithrombin 
III and protein S, should be considered. Thrombo- 
lyric therapy has been used with success in the setting 
of nephrosis-associated renovascular thrombosisY 
Of course, surgical thrombectomy can be success- 
fully accomplished once the measures previously out- 
lined have been instituted, as illustrated by case num- 
ber one. Long-term anticoagulation should be 
maintained as long as nephrotic-range protein loss 
continues but may be discontinued on resolution of 
the nephrotic process. 
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